The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Anidulafungin Teva 100 mg Powder for Concentrate for Solution for Infusion

Teva B.V.PA1986/045/001

Main Information

Trade NameAnidulafungin Teva 100 mg Powder for Concentrate for Solution for Infusion
Active SubstancesAnidulafungin
Dosage FormPowder for concentrate for solution for infusion
Licence HolderTeva B.V.
Licence NumberPA1986/045/001

Group Information

ATC CodeJ02AX Other antimycotics for systemic use
J02AX06 anidulafungin


License statusAuthorised
Licence Issued16/02/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back